Sex-dependent effect of mild hyperhomocysteinemia: a risk factor to neurodegenerative disease, cognitive decline, inflammation and tau expression.
Abstract
Background: Homocysteine (Hcy) is a non-proteic amino acid produced during the metabolism of methionine. Mild hyperhomocysteinemia (HHcy) occurs when Hcy plasma levels are between 16-30 µmol/L, which has been identified as an independent risk factor for neurodegeneration. Although its neurotoxic effects are well-described, the potential for sex-specific differences in susceptibility to mild HHcy-induced cognitive and biochemical alterations remains scarcely investigated. Thus, Hcy could be a potent early biomarker for cognitive decline, and understanding the sex-specific impact of this condition on behavior and tissue is important for establishing its clinical significance. Objective: This study aimed to investigate the effects of mild HHcy in adult male and female rats, examining hippocampal and cortical involvement in memory-related behavioral outcomes. Methods: Adult male and female Wistar rats were treated with 0.03 µmol Hcy/g BW, s.c., from P60 to P90, to induce a model of mild HHcy. Behavioral assessments included the Y-maze, open-field, object recognition, and Morris water maze tests. Post-behavioral test, the rats were euthanized, and the cortex and hippocampus were analyzed for gene expression of inflammatory mediators (IL-6, IL-10), cellular markers (GFAP, AIF1, RbFOX3), and p-TAU217 by RT-qPCR. Results: Our findings revealed that mild HHcy induced long-term and spatial memory impairment in male rats, since they exhibited significant cognitive impairment, with reduced preference and discrimination in the novel object recognition task; in the Morris water maze, HHcy-treated male rats did not learn the task efficiently during training days and also spent more time to find the platform during the probe trial, showing impaired spatial learning and memory. These behavioral deficits were followed by region-specific molecular changes, as HHcy decreased expression of IL-10 and the neuronal marker RbFOX3 in the cortex of males. In the hippocampus, HHcy increased IL-10 and AIF1 expression. In contrast, despite Hcy-treated females traveling significantly more than controls on the probe day, they did not exhibit memory deficits; conversely, HHcy increased the expression of the neurodegeneration marker p-TAU217 and the astrocytic marker GFAP in the cortex, suggesting early tau-related and astroglial responses without overt behavioral and cognitive impairment. Conclusion: Chronic mild HHcy in male adult rats induces significant cognitive impairments, followed by cortical neuronal loss and microglial-associated inflammatory response; meanwhile, female rats displayed resilience to memory deficits despite biochemical alterations in the cortex, which may indicate astrogliosis and neurodegeneration due to tauopathy. These findings reveal marked sex- and region-specific responses to mild HHcy and suggest that it may represent a valuable translational model for studying early-stage cognitive decline and tauopathy, particularly in the context of sex-specific vulnerability. Supported by INCT/SaúdeCerebral/CNPq.